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BSTRACT
 
Background and Methods
 
In preliminary trials, la-
mivudine, an oral nucleoside analogue, has shown
promise for the treatment of chronic hepatitis B. We
conducted a one-year, double-blind trial of lamivu-
dine in 358 Chinese patients with chronic hepatitis B.
The patients were randomly assigned to receive 25
mg of lamivudine (142 patients), 100 mg of lamivu-
dine (143), or placebo (73) orally once daily. The pa-
tients underwent liver biopsies before entering the
study and after completing the assigned treatment
regimen. The primary end point was a reduction of
at least two points in the Knodell necroinflammatory
score.
 
Results
 
Hepatic necroinflammatory activity im-
proved by two points or more in 56 percent of the
patients receiving 100 mg of lamivudine, 49 percent
of those receiving 25 mg of lamivudine, and 25 per-
cent of those receiving placebo (P<0.001 and P=0.001,
respectively, for the comparisons of lamivudine treat-
ment with placebo). Necroinflammatory activity wor-
sened in 7 percent of the patients receiving 100 mg
of lamivudine, 8 percent of those receiving 25 mg,
and 26 percent of those receiving placebo. The 100-
mg dose of lamivudine was associated with a re-
duced progression of fibrosis (P=0.01 for the com-
parison with placebo) and with the highest rate of
hepatitis B e antigen (HBeAg) seroconversion (loss
of HBeAg, development of antibody to HBeAg, and
undetectable HBV DNA) (16 percent), the greatest
suppression of HBV DNA (98 percent reduction at
week 52 as compared with the base-line value), and
the highest rate of sustained normalization of ala-
nine aminotransferase levels (72 percent). Ninety-six
percent of the patients completed the study. The in-
cidence of adverse events was similar in all groups,
and there were few serious events.
 
Conclusions
 
In a one-year study, lamivudine was
associated with substantial histologic improvement
in many patients with chronic hepatitis B. A daily
dose of 100 mg was more effective than a daily dose
of 25 mg. (N Engl J Med 1998;339:61-8.)
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HROUGHOUT the world, over 300 mil-
lion people have chronic infection with hep-
atitis B virus (HBV), and more than 75
percent of those affected are of Asian ori-
gin.
 
1
 
 Chronic HBV infection causes cirrhosis, liver
cancer, and death.
 
2,3
 
 The disease is endemic in Africa
and Asia, where the virus is transmitted from moth-
er to newborn or between close contacts in early
childhood.
 
4-6
 
 Chronically infected persons with viral
replication are at highest risk for progressive liver
disease.
 
7
 
 Cirrhosis and hepatocellular carcinoma ac-
count for more than 50 percent of deaths in Asian
men with chronic infection.
 
3
 
Interferon alfa is currently the only treatment spe-
cifically approved by regulatory authorities through-
out the world for chronic hepatitis B.
 
8,9
 
 It is given
by injection and has potentially dose-limiting side
effects. The efficacy of interferon alfa is variable, but
a meta-analysis showed that 33 percent of patients
receiving the drug had a loss of hepatitis B e antigen
(HBeAg), as compared with 12 percent of untreated
controls.
 
8
 
 Interferon alfa is least effective in Asian
patients,
 
10,11
 
 except those with elevated liver-enzyme
levels.
 
12
 
 The poor response is thought to be due to
T
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immune tolerance to HBV after infection at birth or
in early childhood.
 
12-15
 
Lamivudine, an oral nucleoside analogue, inhibits
viral DNA replication. The drug was well tolerated
in controlled studies in patients with human immu-
nodeficiency virus (HIV) infection at a dose of 600
mg per day for more than one year,
 
16
 
 and in more
than 3000 patients with chronic HBV infection. In
phase 2 studies, all doses studied (5 to 600 mg per
day for up to six months
 
17-20
 
) markedly reduced se-
rum HBV DNA levels in Asians and whites. With
doses of more than 100 mg per day, the median sup-
pression of serum HBV DNA was greater than 98
percent in most patients during treatment. However,
when treatment was stopped, serum HBV DNA lev-
els generally returned to pretreatment values.
We conducted a study to determine whether a long-
er duration of viral suppression (one year) would re-
sult in improved histologic findings, higher HBeAg
seroconversion rates, or both in patients with chron-
ic hepatitis B.
 
METHODS
 
Patients
 
Eligible patients included males and females, 16 to 70 years
old, with detectable hepatitis B surface antigen (HBsAg) and
HBeAg in serum at the time of screening and for at least the pre-
vious six months, serum HBV DNA levels of at least 5 pg per mil-
liliter (as determined with the use of a solution-hybridization as-
say; Abbott Diagnostics, Chicago), and alanine aminotransferase
levels that were less than 10 times the upper limit of normal at
screening and for at least the previous three months. The last cri-
terion was chosen to exclude patients who might have spontane-
ous HBeAg seroconversion at the time of screening. Patients were
excluded if they had hepatitis C or D or HIV infection; decom-
pensated liver disease (defined by a serum bilirubin level more
than 2.5 times the upper limit of normal, a prothrombin time pro-
longed by more than 3 seconds, and a serum albumin level lower
than 3 g per deciliter or a history of ascites, variceal hemorrhage,
or hepatic encephalopathy); or evidence of autoimmune hepatitis
(defined as an antinuclear-antibody titer higher than 1:160). Pa-
tients were also excluded if they had received an investigational
drug within 30 days before enrollment; any systemic antiviral ther-
apy, immunomodulators, cytotoxic agents, or corticosteroids within
6 months; or lamivudine within 3 months.
The study was approved by the ethics committees at the par-
ticipating centers, and all patients gave witnessed oral or written
informed consent before enrollment. No interim analyses were
performed.
 
Study Design
 
The patients were randomly assigned to receive 25 mg of lami-
vudine, 100 mg of lamivudine, or placebo, given orally once a day
for 12 months (ratio of random assignments to the three groups,
2:2:1). All the patients had undergone liver biopsy within six
months before screening. Biopsy specimens were evaluated with
the use of a simplified histologic assessment for periportal and
lobular hepatitis with or without bridging or confluent necrosis.
Patients were assigned to one of two strata on the basis of the
liver-biopsy findings: moderate or severe hepatitis or mild hepa-
titis.
After the first clinic visit (at base line), patients returned during
weeks 2 and 4 and every four weeks thereafter through week 52.
Serum was assayed for HBV DNA (at base line and weeks 2, 4,
8, 12, 24, 36, and 52), HBeAg and antibody to HBeAg (at base
line and weeks 8, 24, 36, and 52), and HBsAg and antibody to
HBsAg (at base line and week 52). At each clinic visit, laboratory
tests were performed to determine the safety of the treatment,
and adverse events since the previous visit were documented.
 
Evaluation
 
A liver biopsy was performed after one year of treatment to
compare results with those of the pretreatment biopsy. Individual
biopsy specimens were scored with the use of the Knodell in-
dex,
 
21
 
 which grades the histologic activity of hepatitis on a scale
from 0 to 22, with higher scores indicating more severe abnor-
malities. The overall Knodell score is the sum of the scores for
periportal bridging necrosis (0 to 10), intralobular degeneration
and focal necrosis (0 to 4), portal inflammation (0 to 4), and fi-
brosis (0 to 4). Response rates were based on the first three com-
ponents of the score (i.e., necroinflammatory activity, on a scale
of 0 to 18).
Before any analyses of the study data were performed, we de-
cided to incorporate a histologic-response variable that would
represent a clinically meaningful change and that could be as-
sessed for each patient. Analysis of changes in the Knodell index
in previous studies of patients with hepatitis B had shown that
there was often an increase of two or more points over a period
of one year, and there was rarely a decrease (i.e., improvement)
of two or more points. Also, a one-point change could be due to
interobserver and intraobserver variability or to biopsy variations
(samples obtained from different parts of the liver). Hence, the
histologic response was defined as a decrease of at least two
points in the Knodell necroinflammatory score at 12 months, as
compared with the base-line score. To reduce the potential for
observer variability, biopsy specimens were evaluated by a single,
independent histopathologist who was unaware of the treatment
assignments and the sequence of the specimens.
The degree of fibrosis and necroinflammatory activity was also
compared in each pair of biopsy specimens (with the investigator
blinded with regard to treatment and biopsy sequence) to deter-
mine whether one specimen showed more severe necroinflamma-
tory activity or more fibrosis (ranked response). Biopsy specimens
were also scored on a scale of 0 to 3 according to the percentage
of cells that were positive for hepatitis B core antigen (HBcAg)
and hepatocyte HBV DNA on immunohistochemical staining
(none, 0; <5 percent, 1; 5 to 25 percent, 2; and >25 percent, 3).
Secondary efficacy variables included HBeAg and HBsAg se-
roconversion, sustained suppression of HBV DNA, and sustained
alanine aminotransferase response, defined as normal values on at
least two consecutive visits, with no two consecutive abnormal
values, or a single normal value at week 52.
 
Assays
 
Staining for HBcAg was performed with rabbit polyclonal an-
tibody to HBcAg (Dakopatts, Copenhagen, Denmark) and indi-
rect avidin–biotin–peroxidase immunohistochemical techniques
(Americium, Chicago) with diaminobenzidine (Sigma, St. Lou-
is).
 
22
 
 Hepatic HBV DNA was localized in hepatocytes with the
use of a nonisotopic in situ hybridization technique and a digox-
igenin-labeled full-length human HBV DNA probe, prepared
from a recombinant plasmid, pHBV130.4.
 
23
 
Virus was assayed at the National University Hospital, Sin-
gapore. Serum HBV DNA was quantified with the use of a solu-
tion-hybridization assay (Abbott) that has a lower limit of detec-
tion of 1.6 pg per milliliter. HBeAg and antibody to HBeAg were
detected by a qualitative HBeAg enzyme immunoassay (Abbott).
HBsAg was detected with a monoclonal qualitative third-genera-
tion enzyme immunoassay (Auszyme, Abbott), and antibody to
HBsAg was detected with the IMX Ausab microparticle enzyme
immunoassay (Abbott).
In previous studies, sequencing of serum samples obtained
from patients before and after treatment with lamivudine has
identified two patterns of mutations that result in changes in the
YMDD (tyrosine, methionine, aspartate, aspartate) region of the
Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
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HBV DNA polymerase and are associated with reduced sensitiv-
ity to lamivudine.
 
24,25 
 
An assay has been developed to detect these
two mutations (a leucine-to-methionine substitution at codon
528 in conjunction with a methionine-to-valine substitution at
codon 552, or a solitary methionine-to-isoleucine substitution at
codon 552). The assay has been used to determine the frequency
and characteristics of the mutations and their clinical effects, if
any. In our study, genotypic analysis was performed with a re-
striction-fragment–length polymorphism assay, which permits
semiquantitative evaluation of mutations at both sites (codons
528 and 552 in the viral polymerase) that are linked to lamivu-
dine resistance. With the use of established standards for mixed
viral-genotype populations (wild-type and mutant HBV), the
lower limit of detection for differentiating between the two viral
genotypes has been determined to be 5 percent of the viral pop-
ulation. The assay has a lower limit of detection of approximately
100,000 copies of viral DNA per milliliter of serum.
 
Statistical Analysis
 
The patients were stratified according to the liver-biopsy find-
ings (moderate or severe hepatitis and mild hepatitis), with the
randomization weighted 2:1. Randomization was performed with
a block size of 15 (10 in the stratum with moderate or severe hep-
atitis, and 5 in the stratum with mild hepatitis). Each center per-
formed randomization for a full block of 15 patients before pro-
ceeding to the next block. The study had 80 percent power to
detect a difference in histologic response between the treatment
groups and the placebo group but not between the two treat-
ment groups.
The intention-to-treat analysis included all patients with con-
firmed chronic hepatitis B who were randomly assigned to a treat-
ment group. Analyses of histologic data were also performed in
patients with pre- and post-treatment biopsy specimens that
could be evaluated and base-line necroinflammatory scores of at
least 2 (so that at least a two-point reduction in the score was
possible). Analyses of safety included data for all patients who
were randomly assigned to a treatment group and received at least
one dose of study medication.
Base-line HBV DNA levels (log
 
10
 
) in the three groups were
compared with the use of analysis of variance
 
26
 
 adjusted for the
center. Differences were tested with Fisher’s exact test or the Coch-
ran–Mantel–Haenszel test adjusted for the center.
 
27
 
 The van
Elteren test was used to compare changes from base line in the
Knodell score among the three groups.
 
28
 
 The time to events was
analyzed with the log-rank test adjusted for all seven centers.
 
26
 
The Wilcoxon rank-sum test was used to compare differences
among the three groups in the percentage change in HBV DNA
levels at week 52.
 
26
 
 All P values are two-sided.
 
RESULTS
 
Study Population
 
The study was conducted between July 1994 and
July 1996. A total of 358 Chinese patients were ran-
domly assigned to receive 25 mg of lamivudine (142
patients), 100 mg of lamivudine (143), or placebo
(73). The intention-to-treat population comprised
357 patients because 1 patient in the placebo group
did not have evidence of HBeAg for six months be-
fore enrollment.
The three groups were similar with respect to
demographic and clinical characteristics and overall
Knodell scores (Table 1). Five percent of the patients
had evidence of cirrhosis at base line on liver biopsy.
The median Knodell necroinflammatory score was 6.
The base-line HBV DNA level was higher in the pla-
cebo group than in either lamivudine group (P=0.04
for the comparison with the 25-mg group, and
P=0.08 for the comparison with the 100-mg group).
Inclusion of base-line HBV DNA levels in a logistic-
regression analysis of histologic responses did not af-
fect the differences we observed among the three
treatment groups.
As expected, the patients with moderate or severe
hepatitis had higher median alanine aminotransfer-
ase values than the patients with mild hepatitis (2.0
vs. 0.9 times the upper limit of normal), a higher
prevalence of cirrhosis (7 percent vs. 0 percent), and
a higher median necroinflammatory score (9 vs. 4).
 
Histologic Findings
 
Changes in the necroinflammatory score could not
be assessed in 12 patients in the placebo group and
24 patients in each of the lamivudine groups because
they either had base-line scores of less than 2 or did
not have pre- and post-treatment biopsy specimens
that could be evaluated. In the intention-to-treat
analysis (in which patients with biopsy data that
were missing or could not be evaluated were consid-
ered to have had no response), both doses of lami-
vudine were more effective than placebo (P<0.001
and P=0.001 for the 100-mg and 25-mg doses, re-
spectively) in reducing necroinflammatory activity
by at least two points (Table 2). There was no sig-
nificant difference in efficacy between the two lami-
vudine doses (P=0.27). The response rates were 49
and 56 percent for the 25-mg and 100-mg doses, re-
spectively, as compared with 25 percent for placebo.
The odds ratio for a response to 100 mg of lamivu-
dine as compared with placebo was 4.0 (95 percent
confidence interval, 2.1 to 7.4).
The results were similar with the analysis of histo-
logic findings in the patients who had base-line
Knodell necroinflammatory scores of at least 2 and
pre- and post-treatment biopsy specimens that could
be evaluated. Improvement in necroinflammatory
activity occurred in 59 percent of the 25-mg group
(70 of 118 patients), 67 percent of the 100-mg
group (80 of 119), and 30 percent of the placebo
group (18 of 60) (P<0.001 for the comparison
between either lamivudine group and the placebo
group). Nineteen of 60 patients in the placebo
group (32 percent) had worsening of histologic
findings, as compared with 12 of 118 patients receiv-
ing 25 mg of lamivudine (10 percent) and 8 of 119
receiving 100 mg (7 percent). The improvements in
necroinflammatory activity were similar in the ranked
assessments of pre- and post-treatment biopsy spec-
imens (Fig. 1). The proportion of patients with wor-
sening of fibrosis was lower in the group receiving
100 mg of lamivudine than in the placebo group
(P=0.01).
The mean base-line Knodell scores were similar in
the three groups (8 in the placebo group, 9 in the
25-mg group, and 8 in the 100-mg group). At week
Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
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52, the mean Knodell scores were lower in the 100-
mg and 25-mg groups (5 and 6, respectively) than
in the placebo group (8). There was a median reduc-
tion of two and three points in the scores in the 25-
mg and 100-mg groups, respectively (indicating im-
provement), as compared with an increase of one
point in the placebo group (indicating worsening).
Immunohistochemical staining of liver-biopsy spec-
imens showed that HBcAg was reduced to the same
extent in the lamivudine and placebo groups and
that there was very little reduction in hepatocyte
HBV DNA in all groups. However, the proportion
of patients with a reduction in cytoplasmic HBcAg
was higher in the two lamivudine groups combined
(46 percent) than in the placebo group (33 percent).
 
HBeAg and HBsAg Seroconversion and Viral Levels
 
At one year, the proportions of patients with
HBeAg seroconversion (loss of HBeAg and the de-
velopment of antibody to HBeAg) and undetectable
levels of HBV DNA were 13 percent in the 25-mg
group (17 of 135 patients) and 16 percent in the
100-mg group (22 of 140), as compared with 4 per-
cent in the placebo group (3 of 70; P=0.08 and
P=0.02, respectively). As compared with the pa-
tients without seroconversion, those with serocon-
version had lower median HBV DNA levels, higher
median alanine aminotransferase levels, and higher
median Knodell necroinflammatory scores at base
line. No patients had undetectable levels of HBsAg
during the study.
In the group of patients receiving 100 mg of lami-
vudine, HBV DNA levels fell rapidly, with a median
reduction of 97 percent after two weeks of therapy
and a median reduction of 98 percent throughout
the study. The percent reduction at week 52 was sig-
nificantly greater in the 100-mg group (98 percent)
than in either the 25-mg group (93 percent) or the
placebo group (54 percent; P<0.001 for both com-
parisons). During treatment, 96 percent of the pa-
tients in the 100-mg group had undetectable HBV
DNA on at least one occasion, as compared with 73
percent of the 25-mg group and 23 percent of the
placebo group (P<0.001 for both comparisons).
 
Alanine Aminotransferase Response
 
Approximately 70 percent of the patients had ele-
vated alanine aminotransferase levels at base line (Ta-
 
*One patient was HBeAg-positive at enrollment but HBeAg-negative at the first visit.
†P=0.04 for the comparison with placebo.
‡Data were available for 333 patients: 68 in the placebo group, 134 in the 25-mg group, and 131
in the 100-mg group.
 
T
 
ABLE
 
 1.
 
 B
 
ASE
 
-L
 
INE
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 S
 
TUDY
 
 P
 
ATIENTS
 
.
 
C
 
HARACTERISTIC
 
P
 
LACEBO
 
(N=72) L
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(N=357)
 
25 mg
(
 
N
 
=142)
100 mg
(
 
N
 
=143)
Age — yr
Median 
Range
29
15–67
33
16–63
31
16–55
32
15–67
Male sex — % 72 73 74 73
Weight — kg
Median 
Range
63.1
38–78
60.3
38–90
63.0
36–100
61.7
36–100
Abnormal alanine aminotransferase levels 
— no. (%)
50 (69) 98 (69) 95 (66) 243 (68)
Positive for HBeAg — no. (%)* 71 (99) 142 (100) 143 (100) 356 (>99)
Positive for antibody to HBeAg — 
no. (%)
2 (3) 0 (0) 6 (4) 8 (2)
Positive for HBsAg — no. (%) 72 (100) 142 (100) 143 (100) 357 (100)
Positive for HBV DNA — no. (%) 70 (97) 135 (95) 140 (98) 345 (97)
Alanine aminotransferase — multiples of 
the upper limit of normal
Median 
Range
1.5
0–10
1.4
0–11
1.5
0–15
1.5
0–15
Serum HBV DNA — pg/ml
Median 
Range
99.4
1–990
70.7
1–763
74.2
1–516
75.2
1–990
Mean ±SD, log
 
10
 
1.85±0.63 1.67±0.62† 1.80±0.54 1.76±0.59
Knodell histologic-activity score — 
no. (%)‡
0–4
5–9
10–14
15–22
17 (25)
28 (41)
14 (21)
9 (13)
31 (23)
52 (39)
29 (22)
22 (16)
24 (18)
57 (44)
38 (29)
12 (9)
72 (22)
137 (41)
81 (24)
43 (13)
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ble 1). Figure 2 shows the time to a sustained ala-
nine aminotransferase response (P<0.001 for either
dose of lamivudine as compared with placebo); 65
percent of the patients in the 25-mg group (64 of
98) and 72 percent of those in the 100-mg group
(68 of 95) had a sustained alanine aminotransferase
response, as compared with 24 percent of the pa-
tients in the placebo group (12 of 50).
 
Genotypic Mutations
 
Analysis of HBV mutations during lamivudine ther-
apy was undertaken with serum samples obtained
from 335 patients at week 52. The incidence of
genotypic mutations in the YMDD locus that confer
a reduced sensitivity to lamivudine was 14 percent in
both lamivudine groups (mixed wild-type and mu-
tant HBV, 9 percent; mutant HBV alone, 5 percent).
These mutations were not detected in any patients
in the placebo group. In the patients with YMDD
mutations, HBV DNA and alanine aminotransferase
levels did begin to rise but did not reach base-line
levels by week 52. YMDD mutations were not asso-
ciated with a decreased histologic response.
 
Safety
 
The study was completed by 94 percent of the pa-
tients in the 25-mg group, 97 percent of those in
the 100-mg group, and 96 percent of those in the
placebo group. Most patients received the assigned
study drug for at least 50 weeks (median, 365 days;
range, 2 to 409). The incidence of adverse events
was similar in all treatment groups (Table 3), with
no significant differences between either lamivudine
group and the placebo group. No patients died, and
none required liver transplantation. 
Five patients (four in the 25-mg group and one in
the 100-mg group) had serious adverse events, al-
though none were considered to be drug-related. In
the 25-mg group, one patient had transitional-cell
carcinoma of the bladder and adenomatous hyper-
plasia of the liver; one had a torn ankle tendon, one
had fever of unknown origin, and one had appendi-
citis requiring surgery. The infant of a patient in the
100-mg group who became pregnant during the
study had cardiac dysrhythmia and mild mitral-valve
prolapse; the baby was asymptomatic, with no signs
of hemodynamic compromise. 
Ten patients had laboratory abnormalities consid-
ered to be of major clinical concern. The incidence
was higher in the group receiving placebo (5 of 73
patients, 7 percent) than in either the group receiv-
ing 25 mg of lamivudine (1 of 142, 0.7 percent) or
the group receiving 100 mg of lamivudine (4 of 143,
3 percent). Three patients in the placebo group, one
in the 25-mg group, and two in the 100-mg group
had abnormal aspartate aminotransferase or alanine
aminotransferase values; one patient in the placebo
group and three in the 100-mg group had elevated
creatine kinase levels (one of the three in the 100-
mg group also had a high alanine aminotransferase
value); and one patient in the placebo group had an
increased amylase level, with ultrasonographic evi-
dence of focal pancreatitis. There was no association
between lamivudine therapy and clinically significant
elevations in serum levels of alanine or aspartate ami-
notransferase, creatine kinase, amylase, or other he-
matologic or biochemical variables.
 
DISCUSSION
 
We found that lamivudine treatment led to signif-
icant histologic improvement in the majority of pa-
tients. In contrast, studies of interferon treatment
have shown histologic improvement primarily in the
few patients with serologic responses. Since the se-
vere sequelae of chronic hepatitis B are due to pro-
gressive liver damage, it is important for treatment
to produce substantial histologic improvement. In
 
*Histologic response was defined as a reduction of two or more points
in the Knodell necroinflammatory score (components 1 through 3) be-
tween base line and week 52. The data are from an intention-to-treat anal-
ysis in which patients with biopsy data that were missing or could not be
evaluated were considered to have had no response.
†P=0.001 for the comparison with placebo.
‡P<0.001 for the comparison with placebo.
§The data are for patients with pre- and post-treatment biopsy specimens
that could be evaluated. Twelve patients in the placebo group and 22 in
each lamivudine group had biopsy data that were missing or could not be
evaluated. Two additional patients in each lamivudine group had base-line
scores of less than 2.
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 H
 
ISTOLOGIC RESPONSES 
AND CHANGES IN THE KNODELL SCORE.
VARIABLE PLACEBO LAMIVUDINE
25 mg 100 mg
Response*
Total
No.
Improvement — no. (%)
Worsening — no. (%)
Patients with moderate or
severe hepatitis
No.
Improvement — no. (%)
Worsening — no. (%)
Patients with mild hepatitis
No.
Improvement — no. (%)
Worsening — no. (%)
72
18 (25)
19 (26)
49
14 (29)
9 (18)
23
4 (17)
10 (43)
142
70 (49)†
12 (8)
100
59 (59)
5 (5)
42
11 (26)
7 (17)
143
80 (56)‡
10 (7)
100
63 (63)
2 (2)
43
17 (40)
8 (19)
Knodell score§
Base line
Median
Mean ±SD
Range
Week 52
Median
Mean ±SD
Range
Change
Median
Mean ±SD
Range
7
8±5
2 to 21
8
8±4
1 to 17
+1
0±4
¡9 to 10
8
9±5
1 to 18
6
6±3
0 to 15
¡2
¡2±4
¡11 to 9
7
8±4
0 to 18
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Figure 1. Improvement or Worsening of Necroinflammatory Activity and Fibrosis in Biopsy Specimens
Obtained before and after Treatment with Lamivudine (25 or 100 mg) or Placebo.
Each pair of specimens was assessed to determine whether one specimen showed more severe necro-
inflammatory activity or more fibrosis than the other (ranked response). As compared with placebo,
lamivudine significantly improved necroinflammatory activity (P<0.001), and the 100-mg dose signif-
icantly reduced the progression of fibrosis (P=0.01). Forty-four patients with available biopsy speci-
mens were not evaluated for a ranked response.
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Figure 2. Cumulative Percentage of Patients with Sustained Alanine Aminotransferase Responses.
The analysis was based on the intention-to-treat principle. P<0.001 for the comparison between each
lamivudine group and placebo.
0
80
0 52
10
20
30
40
50
60
70
4 8 12 16 20 24 28 32 36 40 44 48
Week
Placebo
Lamivudine, 25 mg
Lamivudine, 100 mg
NO. OF PATIENTS WITHOUT RESPONSE
PlaceboH
25 mgH
100 mg
50H
98H
95
48H
91H
94
47H
87H
91
47H
79H
81
47H
71H
69
47H
56H
58
47H
51H
51
46H
44H
46
46H
40H
41
45H
39H
40
43H
38H
35
43H
36H
32
41H
34H
30
38H
34H
27
C
u
m
u
la
ti
ve
 P
er
ce
n
ta
g
e 
o
f 
P
at
ie
n
ts
H
w
it
h
 S
u
st
ai
n
ed
 R
es
p
o
n
se
Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on November 13, 2006 . 
ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B
Volume 339 Number 2 · 67
our study, the placebo group had measurable dete-
rioration in the Knodell scores within a year. Lami-
vudine therapy significantly reversed necroinflamma-
tory activity and induced a sustained normalization
of alanine aminotransferase levels in 68 percent of
the patients. The 100-mg dose of lamivudine also
prevented the progression of fibrosis.
The development of mutant HBV in the lamivu-
dine groups was associated with increases in both
alanine aminotransferase and HBV DNA levels over
the lowest values before the mutations developed,
although at 52 weeks the levels were still lower than
pretreatment values. The histologic improvements
were maintained in spite of the development of mu-
tations. Longer follow-up is needed to determine
the clinical importance of these mutations.
The rate of HBeAg seroconversion was signifi-
cantly higher in the patients receiving 100 mg of
lamivudine per day (16 percent) than in those receiv-
ing placebo (4 percent). In Chinese patients treated
with interferon, the rate of HBeAg seroconversion
(defined as undetectable serum HBV DNA and loss
of HBeAg) is about 20 percent, as compared with
8 percent in controls.12 In our study, the patients
treated with lamivudine in whom HBeAg serocon-
version occurred had lower base-line levels of HBV
DNA and higher base-line alanine aminotransferase
levels than the patients without seroconversion. These
predictors of lamivudine-induced HBeAg serocon-
version are similar to the predictors of interferon-
induced HBeAg seroconversion, even though the
two drugs have different mechanisms of action.12,29
HBeAg seroconversion involves a reversion to a state
of lower HBV replication that is often maintained
for years (relapse rate, 10 to 30 percent). The results
of a recent study in Germany suggest that patients
with hepatitis B and HBeAg seroconversion induced
by interferon alfa are generally at lower risk for clin-
ical disease progression than those without serocon-
version unless advanced cirrhosis is already present at
the time of seroconversion.30 Further studies are re-
quired to determine whether this finding applies to
Chinese patients with hepatitis B who have been
treated with lamivudine and whether lamivudine-
induced HBeAg seroconversion is maintained after
treatment.
In our study, both doses of lamivudine reduced
serum HBV DNA levels, but the degree of suppres-
sion was significantly greater with the 100-mg dose.
This result is in agreement with previous studies
showing that lamivudine at daily doses of 100 mg or
higher produced maximal HBV DNA suppression.17-20 
Lamivudine was well tolerated in our study. In
contrast, an earlier study reported elevated alanine
aminotransferase levels in a few patients,19 a finding
that highlights the importance of concurrent place-
bo controls. The safety profile of lamivudine con-
trasts with that of interferon, which is associated
with influenza-like symptoms, neutropenia, headache,
alopecia, prolonged fatigue, and depression in some
patients. In view of the substantial reductions in
necroinflammatory activity and progression of fibro-
sis with lamivudine and its excellent safety profile,
longer-term treatment should be evaluated.
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APPENDIX
In addition to the authors, the following investigators were members of
the Asia Hepatitis Lamivudine Study Group: University of Hong Kong,
Hong Kong, China — M.F. Yuen and W.M. Wong; Chang Gung Memorial
Hospital, Taipei, Taiwan — Y.F. Liaw; National University Hospital, Sin-
gapore — I. Yap; Singapore General Hospital, Singapore — H.S. Ng and
W.C. Chow; and Glaxo Wellcome — L. Condreay.
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